Phase I Dose Escalation Study of Pirarubicin in Combination with Cyclophosphamide in Breast Cancer

被引：0
|
作者：
Sakata, M. [1 ]
Jinno, H. [1 ]
Hayashida, T. [1 ]
Takahashi, M. [1 ]
Sato, T. [1 ]
Seki, H. [1 ]
Shimada, K. [1 ]
Nishiya, S. [1 ]
Kitagawa, Y. [1 ]
机构：
[1] Keio Univ, Sch Med, Tokyo, Tokyo, Japan
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P5-10-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-10-13
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer
    Dhingra, K
    Frye, D
    Newman, RA
    Walters, R
    Theriault, R
    Fraschini, G
    Smith, T
    Buzdar, A
    Hortobagyi, GN
    CLINICAL CANCER RESEARCH, 1995, 1 (07) : 691 - 697
  • [2] Comparative study: Pirarubicin vs doxorubicin in combination with cyclophosphamide and fluorouracil in the treatment of breast cancer
    Budisic, Z
    Predrijevac, H
    Podolski, E
    Gosev, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 383 - 383
  • [3] Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur uracil
    Osaki, Akihiko
    Mitsuyama, Shoshu
    Kurebayashi, Jun-Ichi
    Sonoo, Hiroshi
    Nishimura, Reiki
    Koga, Toshihiro
    Murakami, Shigeru
    Ohno, Shinji
    ONCOLOGY LETTERS, 2010, 1 (01) : 45 - 49
  • [4] Dose escalation study of carboplatin and cyclophosphamide with filgrastim support - A phase I study
    Toner, GC
    Green, M
    Bishop, JF
    McKendrick, J
    Cebon, J
    Sheridan, WP
    Lockbaum, P
    O'Byrne, J
    Fox, RM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (03): : 263 - 269
  • [5] A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer
    Storniolo, A. M.
    Rubin, P.
    Magrinat, G.
    Parker, B.
    Rush-Tayler, A.
    Sheidler, V
    Aranjo, S.
    Shaw, C.
    Eldreth, N.
    Lott, G.
    Brechlin, J.
    Loftiss, J., I
    Fleming, R. A.
    Weber, B. L.
    CANCER RESEARCH, 2009, 69 (02) : 238S - 238S
  • [6] Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: A dose escalation study
    Bonneterre, J
    Tubiana-Hulin, M
    Catimel, G
    ONCOLOGY, 2004, 66 (03) : 185 - 191
  • [7] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
  • [8] Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
    Murren, JR
    Anderson, S
    Fedele, J
    Pizzorno, G
    Belliveau, D
    Zelterman, D
    Burtness, BA
    Tocino, I
    Flynn, SD
    Beidler, D
    Cheng, YC
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 148 - 157
  • [9] Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
    Thomas, Parijatham S.
    Patel, Anisha B.
    Lee, J. Jack
    Liu, Diane D.
    Hernandez, Mike
    Muzzio, Miguel
    Contreras, Alejandro
    Sepeda, Valerie
    Mays, Carrie
    Weber, Diane
    Vornik, Lana A.
    Khan, Seema A.
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Perloff, Marjorie
    Brown, Powel H.
    CANCER PREVENTION RESEARCH, 2023, 16 (01) : 47 - 56
  • [10] A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer
    Thomas, P. S.
    Patel, A. B.
    Contreras, A.
    Liu, D. D.
    Lee, J. J.
    Khan, S.
    Vornik, L. A.
    Dimond, E. P.
    Perloff, M.
    Heckman-Stoddard, B. M.
    Brown, P. H.
    CANCER RESEARCH, 2019, 79 (04)
12345